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Abstract
Background: Trinity Evolution® cellular bone allograft (TE) possesses the osteogenic, osteoinductive, and
osteoconductive elements essential for bone healing. The purpose of this study is to evaluate the radiographic and
clinical outcomes when TE is used as a graft extender in combination with locally derived bone in one- and two-level
instrumented lumbar posterolateral arthrodeses.
Methods: In this retrospective evaluation, a consecutive series of subject charts that had posterolateral arthrodesis with
TE and a 12-month radiographic follow-up were evaluated. All subjects were diagnosed with degenerative disc disease,
radiculopathy, stenosis, and decreased disc height. At 2 weeks and at 3 and 12 months, plain radiographs were
performed and the subject’s back and leg pain (VAS) was recorded. An evaluation of fusion status was performed at
12 months.
Results: The population consisted of 43 subjects and 47 arthrodeses. At 12 months, a fusion rate of 90.7 % of subjects
and 89.4 % of surgical levels was observed. High-risk subjects (e.g., diabetes, tobacco use, etc.) had fusion rates
comparable to normal patients. Compared with the preoperative leg or back pain level, the postoperative pain levels
were significantly (p < 0.0001) improved at every time point. There were no adverse events attributable to TE.
Conclusions: Fusion rates using TE were higher than or comparable to fusion rates with autologous iliac crest bone
graft that have been reported in the recent literature for posterolateral fusion procedures, and TE fusion rates were not
adversely affected by several high-risk patient factors. The positive results provide confidence that TE can safely replace
autologous iliac crest bone graft when used as a bone graft extender in combination with locally derived bone in the
setting of posterolateral lumbar arthrodesis in patients with or without risk factors for compromised bone healing.
Trial registration: Because of the retrospective nature of this study, the trial was not registered.
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Background
Lumbar arthrodesis is a commonly performed surgical
procedure in the treatment of numerous spinal diagno-
ses including degenerative disc disease, spinal stenosis,
spondylolisthesis, and other deformities. A bony fusion
is essential for restoring segmental stability, preventing
or correcting deformity and, when combined with de-
compression for disorders such as spondylolisthesis with
spinal stenosis, has been shown to provide improved
long-term outcomes [1, 2]. Lumbar intervertebral fusion
is achieved by creating an environment conducive to the
formation of a continuous osseous bridge across the in-
volved spinal segments. Autologous iliac crest bone graft
(ICBG) has historically been the gold standard bone
grafting material used to create this fusion environment
because of its inherent biological characteristics of
osteoconduction (scaffold), osteoinduction (signal), and
osteogenesis (viable cells). However, harvesting of ICBG
requires a second operative site which is associated with
complications such as chronic harvest site pain, infec-
tion, increased operative time, and blood loss [3–7].
Additionally, the quality and quantity of ICBG may be
inadequate especially in older individuals or patients
with significant comorbidities [8, 9].
To counter these issues, a plethora of bone graft substi-
tutes (BGS) have been developed such as freeze-dried
bone allograft, demineralized bone matrices (DBM), syn-
thetic matrices, and recombinant bone morphogenetic
protein (BMP). An ideal BGS should be safe, economical,
and comparable in composition to ICBG so as to contain
a physiologic quantity and quality of viable osteoprogeni-
tor cells, matrix, and signal. However, until recently, none
of the available BGS contained all three components (cells,
signal, matrix) in a single “off the shelf” tissue form.
Trinity Evolution® cellular bone allograft (TE) is a
viable, cryopreserved cellular bone allograft. Cellular
bone allografts consist of viable cancellous bone and
demineralized cortical bone and contain physiologic
amounts of living, healthy osteogenic cells (such as
mesenchymal stem cells and osteoprogenitor cells), sig-
nals (bioactive BMP endogenous to the demineralized
cortical bone), and a scaffold (cancellous matrix) to
which the progenitor cells remain attached [10]. TE is
regulated by the FDA to be a human cell and tissue
product (HCT/P) and is intended for use in bone repair,
replacement, or reconstruction. Due to possessing bio-
logic properties that closely resemble those of autograft,
TE may be well-suited for usage in patients with comor-
bidities such as advancing age, long-term steroid ther-
apy, and cigarette smoking, which may compromise the
quality of autograft and are known to have a negative ef-
fect on bone healing [11]. Previously, TE was evaluated
in foot and ankle arthrodesis procedures in patients with
comorbidities and fusion rates were higher than or
comparable to fusion rates with autograft that were
reported in the literature [12].
To evaluate the clinical results of TE, we conducted a
restrospective study with plain radiographic evaluation
of a population of subjects requiring posterolateral lum-
bar arthrodeses. The purpose of this clinical study was
to review the radiographic and clinical outcomes when
TE is used as a graft extender with locally derived auto-
graft bone. To our knowledge, this is the first clinical re-
port of a cellular bone allograft used in posterolateral
lumbar arthrodesis without interbody arthrodesis.
Methods
Study design
In this retrospective evaluation, a consecutive series of
charts in which the subjects had surgery at a single insti-
tution after June 2009 and who completed their 12-
month visit before October 28, 2014 were screened to
determine whether they met the inclusion criteria. These
criteria included being at least 18 years of age and re-
ceiving posterolateral lumbar (L1-S1) fusion surgery with
decompressive laminectomy that utilized TE that was
mixed with locally derived autograft bone in a one- or
two-level lumbar arthrodesis procedure with supplemen-
tal internal pedicle screw fixation. Patients were ex-
cluded who required more than two-level arthrodeses
and interbody fusions, did not return for a follow-up
visit within the 12 ± 3-month window, or who did not
have flexion/extension films at the 12-month visit. No
restrictions were placed on the diagnosis, which in-
cluded degenerative disc disease, spondylolisthesis (all
grades), scoliosis, radiculopathy, reflex changes, stenosis,
instability, osteophytes, decreased disc height, herniated
nucleus pulposus, facet joint degeneration, and/or vac-
uum phenomenon. The Western Institutional Review
Board approved this study (number 1150670) and
waived the requirement to obtain consent.
Surgical procedure
All patients underwent open decompressive laminec-
tomy, medial facetectomy, and posterolateral arthrodesis
with pedicle screw instrumentation with intraoperative
fluoroscopic assistance.
Decompressive laminectomy was performed by remov-
ing approximately the inferior two thirds of the cephalad
spinous process and lamina and approximately the
superior half of the caudal spinous process and lamina
and intervening ligaments extending laterally to include
medial facetectomy. Complete facetectomy was avoided.
Foraminotomies were performed when necessary. The
preparation of TE (Orthofix, Inc., Lewisville, TX, proc-
essed by Musculoskeletal Transplant Foundation, Edison,
NJ) in the operating room prior to implantation was stan-
dardized in accordance with the instructions for use as
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previously described [13]. All locally harvested bone was
obtained from resected spinous processes, laminae, and
medial facets and stripped of soft tissue and morselized.
The volume was reliably measured in a graduated, clear
medicine cup prior to mixing with TE.
Meticulous decortication of the transverse processes,
the lateral facet joint, and the facet joint itself was per-
formed with a power burr. The combined morselized
local autograft and TE was packed across the decorti-
cated transverse processes and intertransverse space and
into the facet joints bilaterally.
Postoperative management and data collection
The charts were reviewed for a total of three postopera-
tive visits that occurred at 2 weeks and at 3 and
12 months. At each time point, the visual analogue scale
(VAS) for leg and back pain, adverse reactions, and plain
radiographs were collected. During surgery, the volumes
of local bone and TE implanted and the volume of blood
loss were recorded. At the 12-month visit, four lumbar
plain radiographic views (anterior-posterior, neutral lat-
eral, and lateral flexion and extension) were obtained
using a digital system.
The chart review showed that pulsed electromagnetic
field (PEMF) stimulation (Spinal Stim®; Orthofix, Lewisville,
TX) was prescribed for all four subjects that received a
two-level arthrodesis and in two subjects that received a
one-level procedure.
Patient age, gender, body mass index (BMI), race, work-
ing status, diagnosis, and comorbidities (nicotine, diabetes,
osteoporosis, and steroid dependence) were collected.
Radiographic evaluation
After a subject met inclusion/exclusion criteria and was
included in the study, the investigator, who was not
blinded to the treatment group, performed an evaluation
of the 12-month plain radiographs stored on a PACS










Underweight (<18.5) 0 (0)
Normal weight (18.5-24.99) 5 (11.63)
Overweight (25–29.99) 11 (25.58)
Obese (30–39.99) 24 (55.81)
Morbidly obese (≥40) 3 (6.98)
Race
Unknown/undisclosed 1 (2.33)




Workers compensation 1 (2.33)
Disabilitya 5 (14.71)
aOnly 34 subjects had information on disability status; workers compensation,
and disability do not overlap
Table 2 Surgical factor frequency













Grade I 32 (78.05)
Grade II 9 (21.95)
Scoliosis 11 (25.58)
Radiculopathy 43 (100)




Decreased disc height 43 (100)
Herniated nucleus pulposis 5 (11.63)
Facet joint degenration 41 (95.35)
Vacuum phenomenon 0 (0)
Other (facet cyst) 4 (9.31)
Local bone volume
<10 cc 8 (18.6)




aThere were a total of 47 levels treated
bAll relevant diagnoses could be selected for each subject
cPulsed electromagnetic field stimulation
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(SECTRA IDS7) and viewed on a high-definition moni-
tor. Prior to study onset, a fused criterion was defined
which required both bridging bone (unilateral or bilat-
eral bridging bone would be considered fused) and angu-
lar vertebral motion less than or equal to 4° on flexion/
extension lateral plain radiographs. The investigator
evaluated the anterior/posterior (A/P) radiograph and
denoted either “yes” or “no” for bridging bone and also
denoted which side was bridged or whether bridging
was bilateral. For motion determination, the Cobb angles
between the superior endplates of each treated level on
flexion and extension radiographs were measured using
the PACS software and the difference calculated. In two-
level procedures, both levels had to be fused for the sub-
ject to be classified as fused.
Statistical methods
Student’s t test was performed to compare the mean
back or leg pain at each follow-up time to the base-
line values. Student’s t test was also used to deter-
mine if the mean volumes of TE and autograft bone
varied between subjects who fused and subjects who
did not fuse.
Fisher’s exact test was utilized to evaluate the subgroups
stratified among various treatment, risk, or demographic
factors for the potential association with fusion outcome.
SAS 9.4 software was used for all statistical evaluations.
Data are reported as mean ± SD, and the significance
levels for all tests were set at a p value of less than 0.05.
Results
Forty-three subject charts were enrolled in the study,
and arthrodesis was performed at 47 levels.
Baseline characteristics
Of the 43 subjects, 63 % were female and 37 % were male
with the mean age of 64.50 ± 10.5 years (age range, 44 to
85). The demographics, comorbidities, and diagnoses
varied across the patient population (Tables 1, 2, and 3).
All subjects were diagnosed with degenerative disc disease
(DDD) and its sequelae such as radiculopathy, stenosis,
and decreased disc height. Twenty-five percent of the
surgical population was diagnosed with scoliosis. Ninety-
five percent were diagnosed with spondylolisthesis (78 %
grade I, 22 % grade II). Eighty-eight percent of the subjects
were overweight, obese, or morbidly obese (BMI at least
Table 3 Risk factor frequency













aNone of the subjects with diabetes were insulin dependent
Table 4 Fusion status at 12 months
Fusion at
12 months
Per subject Per level
n (%) n (%)
Fuseda 39 (90.7) 42 (89.4)
Not fused 4 (9.3) 5 (10.6)
aFused requires both bridging bone and angular vertebral motion ≤4° on
flexion/extension lateral plain radiographs per level and both levels to be
fused per subject. Fusion was analyzed post hoc
Fig. 1 Twelve-month visit AP radiograph. Subject that was diagnosed
with grade II degenerative spondylolisthesis and osteoporosis and that
was treated with osteoporosis-related medications. Subject received
15 cc TE and 10 cc locally derived autograft. Robust bilateral bone
bridging observed at 10.5 months. Patient fell at 6 months postoperatively
and obtained a T9 compression fracture, although this apparently
had no adverse effect on the fusion mass
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25 to more than 40), 9 % of the subjects were non-insulin-
dependent diabetics, and 9 % were smokers. Thirty-nine
subjects (90.7 %) received fusion at one level and four
(9.3 %) received fusion at two levels. Arthrodeses were
performed 7 times at L3-L4 and 40 times at L4-L5. No
lumbar-sacral fusions were performed. No complications
were reported intraoperatively. Postoperative blood trans-
fusion was performed in 4.6 % of the patients.
Fusion
At 12 months, a fusion rate of 90.7 % of the subjects
and 89.4 % of surgical levels was observed (Table 4,
Figs. 1 and 2) using the radiographic criteria established
prior to the study. Facet fusion could not be assessed
from plain radiographs, but may have contributed to de-
creased motion as indicated in one subject that had less
than 4° of motion, but no bridging bone. The incidence
of bridging bone was not significantly different between
the two levels (85.7 % for L3-L4 and 87.5 % for L4-L5).
In some cases, robust bridging bone was observed as
early as 3 months (Fig. 2).
Three subjects did not meet the fused criteria but were
asymptomatic. One subject received a two-level arthrod-
esis that showed signs of bridging bone at 3 months
before the patient had a falling accident. The other two
subjects received a single-level arthrodesis.
The mean volume of TE or autograft was similar and
not statistically different in subjects that successfully
fused compared to subjects that did not fuse (Table 5).
Per arthrodesis level, the TE volume mean was 12 ±
2.5 cc (range of 10 to 15 cc). The local bone volume
mean was 11.1 ± 2.7 cc (range of 5 to 20 cc). The mean
total volume of the combined graft was 22.6 ± 4.0 cc
(range for one-level procedures was 15–30 cc and the
range for two-level procedures was 30–45 cc). Fusion
was observed in two patients that had a low volume of
autograft bone (5 and 8 cc) that contributed to the vol-
ume mass.
The subgroups were stratified among various diagno-
ses, risk, and demographic factors and evaluated for the
potential association with fusion outcome. With the
numbers provided, there were no significant differences
detected in fusion rates among subjects who were normal
weight as compared to subjects who were overweight,
obese, or morbidly obese; were diabetic as compared to
those who were not; had never used or who were former
or current tobacco users; were male or female; were over
or under the age of 65; received a two-level or a one-level
arthrodesis; received or did not receive bone growth
stimulation; or were or were not steroid dependent
(Table 5).
Clinical findings
There were statistically significant improvements in both
leg and back pain outcomes after surgery. Compared
with the preoperative leg or back pain level, the postop-
erative pain levels were significantly (p < 0.0001) im-
proved at every time point (Figs. 3 and 4). The mean
improvement in the leg pain VAS scores from baseline
to 2 weeks and 3 and 12 months was 6.2, 5.5, and
5.3 cm, respectively. For back pain, the mean improve-
ment in VAS scores from baseline to 2 weeks and 3 and
12 months was 3.9, 4.3, and 4.2 cm, respectively. A com-
parison between subjects greater than 65 years old and
Fig. 2 Baseline, 2-week, and 2- and 12-month AP radiographs. These radiographs show maturation of robust bilateral bridging bone over time.
Subject was a non-insulin-dependent diabetic patient with grade I degenerative spondylolisthesis. Subject received 10 cc of TE and 15 cc of
locally-derived autograft. a Baseline. b 2 weeks. c 2 months. d 12 months
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those less than 65 years old revealed no significant
differences for either leg or back pain at any time point.
One subject (2.3 %) exhibited a neurological deficit
(worsening leg pain) at 3 months, which was resolved by
12 months.
Safety
There were no adverse events that were related to TE/
autograft. There were no infections attributed to the graft
material, and there were no deep infections. Two subjects
(4.7 %) had superficial infections that were treated with
irrigation, debridement, and antibiotics without sequelae.
There were three revision surgeries (7 %). Dislodged
hardware caused one revision, and this patient was
subsequently fused at 12 months. Two were caused by
adjacent level symptomatic stenosis. There were no revi-
sions attributed to symptomatic pseudoarthrosis.
Discussion
This retrospective, open-label study evaluated fusion and
clinical outcomes for Trinity Evolution® cellular bone
allograft (TE) combined with local bone in subjects who
underwent decompressive lumbar laminectomy and
one- or two-level posterolateral arthrodesis with supple-
mental pedicle screw fixation. To our knowledge, this is
the first clinical report of a cellular bone allograft used
for posterolateral fusions (PLF). The usage of TE did not
raise any safety concerns since there were no adverse
events, deep infections, or symptomatic pseudoarthroses
related to TE. Subject leg and back pain significantly
improved at every time point as compared to baseline
with improvements that were above the minimal clinic-
ally important difference [14].
Although ICBG has been considered the gold stand-
ard for lumbar spine arthrodesis, it is associated with
significant, well-documented morbidity [15–17] and
potential limitations (quality and quantity). For instru-
mented posterolateral arthrodesis, the reported fusion
rate for ICBG varied from 54 to 100 % [1, 18–24]. A
comparison to one of these studies that had a similar
patient population of single-level symptomatic spinal
stenosis and spondylolisthesis revealed a comparable
bridging bone fusion rate, but the mean angular mo-
tion was much higher (4.2° versus 1.1° in this study)
[1]. From the current study, the 90.7 % fusion rate of
TE used as a graft extender with locally derived auto-
graft bone compares favorably with the reported ICBG
fusion rate and mitigates the morbidity associated with
ICBG harvest. In addition, TE as a graft extender was
associated with fusion even in cases with low quantities
of local bone.
Comorbidities such as age, tobacco use, steroid de-
pendence, and diabetes have been linked to higher rates
of non-union or delayed union and inhibition of bone
repair and are associated with higher complication rates
[11, 25–28]. We therefore stratified these groups out of the
entire population to determine if fusion rates would be
impacted. Subgroup comparison of those patients who
were overweight, greater than or equal to 65 years of age,
diabetic, tobacco/nicotine users, steroid dependent, and
Table 5 Fusion status at 12 months stratified on various
treatment, risk, or demographic factors
Demographic % fused (#/n)
Weight status
Normal weight (18.5–24.99) 100 (5/5)
Overweight (25–29.99) 81.8 (9/11)
Obese (30–39.99) 94.1 (16/17)























<10 cc per level 75.0 (6/8)










Musante et al. Journal of Orthopaedic Surgery and Research  (2016) 11:63 Page 6 of 9
had more than one level fused showed no significant differ-
ences in fusion rates as compared to their counterparts.
Since the sample size was small for several of these popula-
tions, the results must be interpreted with caution. One
possibility to explain the maintenance of fusion rates even
for these high-risk patient groups may be that TE mitigated
the increased risk of pseudoarthrosis for these subjects.
The exception for small sample sizes was the elderly
population, which contained a larger and more balanced
population size than the other subgroups. Elderly pa-
tients have more overall health issues with multiple
medical comorbidities that contribute to difficulty achiev-
ing successful fusion with autograft [1, 29, 30]. One poten-
tial explanation for the lack of a decrease of fusion rate
that was observed between the older and younger patient
subgroups is that the consistent levels of viable, healthy
osteogenic cells within TE were able to compensate for
the decreased cellular quantity and quality of the cells
within autograft derived from elderly individuals. In order
to draw any definitive conclusions, a prospective and
ideally randomized, controlled study design would be re-
quired with comparisons made between high-risk and
normal subject cohorts.
Published literature on cellular bone allografts supports
the positive radiographic and clinical findings reported
herein. In a prospective study that evaluated the safety
and effectiveness of TE in single-level anterior cervical
discectomy and fusion, the fusion rate was 93.5 % at
Fig. 3 Back VAS pain scores at baseline, 2 weeks, and at 3 and 12 months. At each time-point, the bars from left to right indicate scores for the
entire population, subjects aged less than 65 years old, and those 65 years and older. Change in back VAS pain from baseline to each follow-up
time point was significant (p < 0.0001) in all populations
Fig. 4 Leg VAS pain scores at baseline, 2 weeks, and at 3 and 12 months. At each time-point, the bars from left to right indicate scores for the
entire population, subjects aged less than 65 years old, and those 65 years and older. Change in leg VAS pain from baseline to each follow-up
time point was significant (p < 0.0001) in all populations
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12 months, no serious allograft-related events occurred
and comparisons to the literature revealed that TE may
help negate any physiological barriers to fusion associated
with high risk factors [31]. TE was evaluated in foot and
ankle arthrodesis procedures, and fusion rates were higher
than or comparable to fusion rates with autograft that
were reported in the literature [12]. An earlier version of
TE (Trinity Matrix) has previously been shown to be
effective for healing foot fracture non-unions and avascu-
lar necrosis [32, 33], demonstrated equivalence to auto-
graft in patient satisfaction and fusion rates [34], and
showed favorable safety and effectiveness outcomes in 23
revision foot and ankle surgery procedures [35].
A limitation to this study was that TE was utilized as a
graft extender with locally derived bone, and there was
no control group that contained either TE or autograft
alone. Additionally, six cases utilized bone stimulators as
an adjunct. Thus, the sole contribution of TE in the
promotion of fusion cannot be ascertained. Additionally,
this was a single center study with one surgeon and thus
does not capture outcomes with alternative operative
approaches or fixation. Furthermore, the surgeon evalu-
ated that the fusion status and surgeon bias is known
with respect to evaluation of other clinical outcome pa-
rameters. This potential bias was mitigated by a fusion
definition that was established prior to subject enroll-
ment and was required to be met independently of clin-
ical outcome. Reduction of bias was demonstrated upon
review of several case charts in which the surgeon ori-
ginally recorded the subject as fused and the subject
doing well during routine clinical follow-up, but upon
re-reading of the films during the study and performed
independently of outcome, the fusion status was re-
versed to radiographic pseudoarthrosis. Additionally, al-
though fusion was assessed using plain films in
combination with motion, the surgeon’s standard of care
did not utilize thin cut computed tomography (CT). CT
can increase the specificity of observing bridging bone
and may also decrease the false positive rate. Lastly, the
retrospective design has inherent shortcomings that in-
cluded subjects that may not return within the 12-month
visit window. Most subjects who did not return for their
12-month visit had early favorable outcomes. Retrospect-
ive designs may have few standardized clinical outcome
measures since they are usually subject to standard of care
practices. Although this study did collect pain information
in the form of patient-generated lower back and leg VAS
questionnaires, more comprehensive functional measures
such as Oswestry Disability Index were not part of this
clinician’s standard practice.
Conclusions
In conclusion, the results of this clinical study suggest
that TE combined with local bone achieves high rates of
fusion as compared to the literature in a broad patient
population, including those at high risk for complica-
tions and older patients representative of the Medicare
population. TE possesses the osteoconductive, osteoin-
ductive, and osteogenic biological properties of autograft
bone, while avoiding donor site morbidity and limited
quantity issues of iliac crest autograft as well as add-
itional operating room time associated with harvesting
autogenous iliac crest bone. Therefore, TE potentially
provides important advantages to both the patient and
the surgeon. In addition, since TE is exclusively derived
from donors that undergo a very strict screening process
and each lot is tested to meet specific criteria regarding
cell viability and BMP-2 content, the potential decreased
potency of autograft derived from older or high-risk
patients may be avoided when TE is utilized as an
extender. Appropriately powered randomized controlled
studies with longer follow-up times that compare TE to
autograft are warranted in the future.
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